# EDGAR Filing Document

**Accession Number:** 0001570562
**File Stem:** 0001570562-25-000094
**Filing Date:** 2025-8
**Character Count:** 34195
**Document Hash:** fb9e384e1a4ca0b4e8bd64c85f258cc7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001570562-25-000094.hdr.sgml**: 20250805

**ACCESSION NUMBER**: 0001570562-25-000094

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250801

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250805

**DATE AS OF CHANGE**: 20250805

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evolus, Inc.
- **CENTRAL INDEX KEY:** 0001570562
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 461385614
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38381
- **FILM NUMBER:** 251184945

**BUSINESS ADDRESS:**
- **STREET 1:** 520 NEWPORT CENTER DRIVE
- **STREET 2:** SUITE 1200
- **CITY:** NEWPORT BEACH
- **STATE:** CA
- **ZIP:** 92660
- **BUSINESS PHONE:** (949) 284-4555

**MAIL ADDRESS:**
- **STREET 1:** 520 NEWPORT CENTER DRIVE
- **STREET 2:** SUITE 1200
- **CITY:** NEWPORT BEACH
- **STATE:** CA
- **ZIP:** 92660

?xml version='1.0' encoding='ASCII'? eols-20250801

 **UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 1, 2025**

**EVOLUS, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38381** | **46-1385614** |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission File Number)** | **(I.R.S. Employer**<br>**Identification No.)** |

---

**520 Newport Center Drive, Suite 1200**

**Newport Beach, California 92660**

**(Address of principal executive offices) (Zip Code)**

**(949) 284-4555**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| <u>Title of Class</u> | <u>Trading Symbol(s)</u> | <u>Name of each exchange on which registered</u> |
| **Common Stock, par value $0.00001 per share** | **EOLS** | **The Nasdaq Stock Market LLC**<br>**(Nasdaq Global Market)** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

------

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.**

On August 5, 2025, the Evolus, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

**Item 5.02&nbsp;&nbsp;&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

*Appointment of David Moatazedi as Principal Financial Officer*

On August 1, 2025, the Company's Board of Directors appointed David Moatazedi, the Company's President and Chief Executive Officer, to serve as Principal Financial Officer of the Company until a new Principal Financial Officer is appointed.

There is no additional compensation associated with Mr. Moatazedi's appointment to Principal Financial Officer. Biographical information for Mr. Moatazedi and information regarding certain related party transactions disclosable pursuant to Item 404(a) of Regulation S-K involving Mr. Moatazedi are reported in the Company's <u>[Proxy Statement on Schedule 14A](https://www.sec.gov/ix?doc=/Archives/edgar/data/1570562/000157056225000066/eols-20250425.htm)</u> filed with the SEC on April 25, 2025.

Mr. Moatazedi has no family relationships with any director or executive officer of the Company, and there are no arrangements or understandings with any person pursuant to which he will be selected as an officer of the Company.

*Departure of Chief Marketing Officer*

On August 4, 2025, the Company announced the departure of Tomoko Yamagishi-Dressler from her role as the Chief Marketing Officer of the Company, effective as of August 22, 2025. Mrs. Yamagishi-Dressler's departure was mutually agreed to with the Company and did not result from any disagreement with the company on any matter relating to the Company's operations, policies or practices.

In connection with her departure, Mrs. Yamagishi-Dressler is entitled to receive severance benefits consistent with the terms of her employment agreement with the Company, which was filed as <u>[Exhibit 10.2](https://www.sec.gov/Archives/edgar/data/1570562/000157056223000115/a93023ex102-tomokoemployme.htm)</u> to the Company's Quarterly Report on Form 10-Q filed on November 7, 2023. No other compensatory arrangements were entered into or amended in connection with her separation.

------

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 99.1 | <u>[Press Release of Evolus, Inc., dated August 5, 2025](q22025eolsex991.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

&nbsp;&nbsp;&nbsp;&nbsp;

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **Evolus, Inc.** | **Evolus, Inc.** |
| Dated: August 5, 2025 | | /s/ David Moatazedi |
| | | David Moatazedi |
| | | President and Chief Executive Officer |

---

## Exhibit 99.1

![image.jpg](image.jpg)

**Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Global Net Revenue of $69.4 Million for Q2 2025, Up 4% from Q2 2024 in a Market Where Overall U.S. Aesthetic Procedures Decreased; Growth Driven by the Successful Launch of Evolysse™ and Continued Strength in International Markets*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Evolysse™ Delivered $9.7 Million in Revenue for Q2 2025, Marking the Strongest Filler Launch Quarter in Over a Decade and Providing a Solid Foundation for Second Half Growth*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Expects to Achieve Meaningful Profitability*<sup>1</sup> *in Q4 2025 and Annual Profitability*<sup>1</sup> *Beginning in 2026; Strategic Cost Structure Optimization Expected to Yield At Least $25 Million in Non-GAAP Operating Expense Savings for 2025*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Resets 2025 Net Revenue Guidance to $295 Million to $305 Million; Rebases 2025 Non-GAAP Operating Expenses to $208 Million to $213 Million; Maintains Projected Total Net Revenue Goal of $700 Million and Non-GAAP Operating Income Margin of 20% by 2028*

**NEWPORT BEACH, Calif., August 5, 2025** – Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the second quarter ended June 30, 2025.

"U.S. toxin demand softened in the second quarter, driven by reduced patient demand due to a sharp decrease in consumer sentiment which resulted in accounts purchasing lower volumes acutely felt in the final two weeks of the quarter. Despite these challenges, Jeuveau<sup>®</sup> continues to outperform the market, maintaining our 14% market share through the first half of 2025 and reinforcing the strength of our brand and customer base," said David Moatazedi, President and Chief Executive Officer of Evolus. "At the same time, the launch of Evolysse<sup>™</sup> surpassed all expectations and marked the strongest first quarter for any filler entrant in over a decade, providing a meaningful start to our evolution into a multi-product performance beauty company. In addition, our international business delivered exceptional growth, highlighting the increasing demand for our product outside the U.S. and the growing global relevance of our brand."

"We took decisive action to offset the reduction in revenue and near-term outlook by optimizing our cost structure, thoughtfully reducing operating expenses, and to maintain our ability to achieve positive non-GAAP operating income in the fourth quarter," Moatazedi continued. "Looking ahead, multiple industry surveys point to an incremental improvement in the U.S. toxin market which is reflected in our business. The second quarter was not representative of our expectations for the back half of the year, which we project to deliver meaningful growth and keep us on track to achieve our $700 million revenue target by 2028."

**Second Quarter 2025 Highlights and Recent Developments**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The company's key performance indicators demonstrated continued momentum during the second quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Total purchasing accounts increased by 565 in the second quarter, bringing the total number of customers purchasing since launch to over 16,500 and surpassing over 55% account penetration in the U.S. The reorder rate among customers remains at approximately 70%<sup>2</sup>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Members in the Evolus Rewards™ consumer loyalty program grew by over 83,000 to over 1.2 million<sup>3</sup>, representing a total increase of 36% as compared to Q2 2024.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Total Evolus Rewards™ redemptions for the quarter continue to grow and hit an all-time high of over 224,000<sup>3</sup> with existing patients receiving repeat treatments at the rate of approximately 65%, which demonstrates growing consumer adoption and utilization.

**Second Quarter 2025 Financial Results**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total net revenues for the second quarter of 2025 were $69.4 million, a 4% increase over the second quarter of 2024, driven by the highly successful launch of Evolysse™ and strong international growth. Net revenue for the second quarter of 2025 included $59.7 million of toxin revenue and $9.7 million of injectable hyaluronic acid (HA) gels revenue.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross profit margin and adjusted gross profit margin were 65.3% and 66.5%, respectively. Adjusted gross profit margin excludes amortization of intangible assets. Gross margins in the quarter were impacted by a higher mix of international sales and introductory pricing offers for Evolysse™ to accelerate adoption.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP operating expenses for the second quarter of 2025 were $55.5 million, including investments to support the launch of Evolysse™, as compared to $61.8 million in the first quarter of 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP operating expenses for the second quarter of 2025 were $54.0 million, compared to $52.9 million in the first quarter of 2025. Non-GAAP operating expenses exclude stock-based compensation expense, revaluation of the contingent royalty obligation, and depreciation and amortization.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP loss from operations for the second quarter of 2025 was $10.2 million, compared to $7.7 million in the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Non-GAAP loss from operations in the second quarter of 2025 was $7.9 million compared to Non-GAAP income from operations $1.1 million in the second quarter of 2024. The 2025 results include investments in support of the launch of Evolysse™ Form and Evolysse™ Smooth injectable HA gels. Non-GAAP loss from operations excludes stock-based compensation expense, revaluation of the contingent royalty obligation, depreciation and amortization, and amortization of intangible assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash and cash equivalents on June 30, 2025 were $61.7 million compared to $67.9 million on March 31, 2025. The decrease in cash during the quarter was primarily driven by increased inventory purchases as the company pulled forward product ahead of increased tariffs on the European Union and threatened tariffs on pharmaceuticals.

**Current Outlook - Evolus Expects:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total net revenues for the full-year 2025 to be between $295 million and $305 million, representing 11% to 15% growth over 2024 results. Company increases Evolysse<sup>™</sup> injectable HA gels contribution to 10% to 12% of total revenue for the full-year 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Full-year non-GAAP operating expenses for 2025 to be between $208 million and $213 million, reflecting strategic cost structure optimization that is expected to yield at least $25 million in non-GAAP operating expense savings for 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• To achieve meaningful profitability<sup>1</sup> in Q4 2025 and annual profitability<sup>1</sup> beginning in 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• To launch in the United States: Evolysse<sup>™</sup> Sculpt in 2026 and Evolysse<sup>™</sup> Lips in 2027.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• To continue to introduce Estyme<sup>®</sup> in Europe through a limited experience program with select physician partners and expand global experience with the product's performance in the second half of 2025. A broader European launch is now planned for Q1 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Total net revenue of $700 million by 2028, based on the combination of its existing aesthetic neurotoxin business and launch of Evolysse<sup>™</sup> in 2025 and Estyme<sup>®</sup> in 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• To achieve non-GAAP operating income margins of 20% by 2028 by leveraging its highly synergistic, existing infrastructure.

**The Company Noted:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Based on the recently announced trade deal with the European Union, starting on August 7, Evolysse<sup>™</sup> will be subject to a 15% tariff. This tariff is expected to have a minimal impact and has been fully incorporated into our guidance. We are actively monitoring developments and remain focused on mitigating any potential future exposure.

------

**Conference Call Information**

Management will host a conference call and live webcast to discuss Evolus' financial results today at 4:30 p.m. ET. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect to the live webcast via the link on the Investor Relations page of our website at www.evolus.com.

Following the completion of the call, an audio replay can be accessed for 48 hours by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13754888. An archived webcast, which will remain available for 30 days, can also be accessed on the Investor Relations page of our website at www.evolus.com.

**About Evolus, Inc.** 

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau<sup>®</sup> (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse<sup>™</sup>, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

1 "Profitability" is not a measure presented in accordance with GAAP. Within this press release, "profitability" is defined as achieving positive non-GAAP operating income. See "Use of Non-GAAP Financial Measures" below for more information on the company's use and definitions of non-GAAP measures.

2 Represents cumulative statistics from the launch of Jeuveau<sup>®</sup> in May 2019 through June 30, 2025.

3 Represents cumulative statistics from the launch of Evolus Rewards<sup>TM</sup> in May 2020 through June 30, 2025.

**Use of Non-GAAP Financial Measures**

Evolus' financial results are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). This press release and the reconciliation tables included in the financial schedules below include adjusted gross profit, adjusted gross profit margin, non-GAAP operating expenses, non-GAAP (loss) from operations, and non-GAAP operating income margin. Adjusted gross profit is calculated as gross profit excluding amortization of an intangible asset. Adjusted gross profit margin is defined as adjusted gross profit as a percentage of total net revenues. Non-GAAP operating expenses, non-GAAP (loss) from operations, and non-GAAP operating income margin exclude (i) the revaluation of contingent royalty obligations, (ii) stock-based compensation expense, and (iii) depreciation and amortization. Management believes that adjusted gross profit and adjusted gross profit margin are important measures for investors because management uses adjusted gross profit margin as a key performance indicator to evaluate the profitability of sales without giving effect to costs that are not core to our cost of sales, such as the amortization of an intangible asset. Management believes that non-GAAP operating expenses, non-GAAP (loss) from operations, and non-GAAP operating income margin are useful in helping to identify the company's core operating performance and enables management to consistently analyze the period-to-period financial performance of the core business operations. Management also believes that non-GAAP operating expenses, non-GAAP (loss) from operations, and non-GAAP operating income margin will enable investors to assess the company in the same way that management assesses the company's operating performance against comparable companies with conventional accounting methodologies. The company's definitions of adjusted gross profit, adjusted gross profit margin, non-GAAP operating expenses, non-GAAP (loss) from operations, and non-GAAP operating income margin have limitations as analytical tools and may differ from other companies reporting similarly named measures. Non-GAAP measures should not be considered measures of financial performance under GAAP, and the items excluded from such non-GAAP measures should not be considered in isolation or as alternatives to financial statement data presented in the financial statements as an indicator of financial performance or liquidity. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP but should not be considered a substitute for or superior to GAAP results.

For a reconciliation of our historical adjusted gross profit, adjusted gross profit margin, non-GAAP operating expenses, non-GAAP (loss) from operations presented herein to gross profit, gross profit margin, GAAP operating expenses and GAAP (loss) from operations, the most directly comparable GAAP financial measures,

------

please see "Reconciliation of Gross Profit Margin to Adjusted Gross Profit Margin," "Reconciliation of GAAP Operating Expenses to Non-GAAP Operating Expenses" and "Reconciliation of GAAP (Loss) from Operations to Non-GAAP (Loss) from Operations" in the financial schedules below. In addition, this press release includes information regarding the company's expected non-GAAP operating expenses and non-GAAP operating income for the full year 2025 and non-GAAP operating income margin by 2028. Evolus has not provided a reconciliation of such forward-looking non-GAAP operating expenses, non-GAAP operating (loss), or non-GAAP operating income margin because a reconciliation of such measures to forward-looking GAAP operating expenses, GAAP loss from operations, and non-GAAP operating income margin respectively, the most directly comparable GAAP financial measures, is not available without unreasonable efforts. This is due to the inherent difficulty of forecasting the timing or amount of various reconciling items that would impact the forward-looking outlook for these non-GAAP financial measures since they have not yet occurred and/or cannot be reasonably predicted. Such unavailable information could have a significant impact on Evolus' GAAP financial results.

**Forward-Looking Statements** 

This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements about future or anticipated events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical or current facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, or other comparable terms intended to identify statements about the future. The company's forward-looking statements include, but are not limited to, statements related to anticipated product launches; market growth and consumer demand; the company's financial outlook for 2025 and beyond; and the company's expectations and timing for achieving continued profitability.

The forward-looking statements included herein are based on our current expectations, assumptions, estimates and projections, which we believe to be reasonable, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to uncertainties associated with our ability to comply with the terms and conditions in the Medytox Settlement Agreements, our ability to fund our future operations or obtain financing to fund our operations, unfavorable global economic conditions including trade disputes and tariffs and the impact on consumer discretionary spending, uncertainties related to customer and consumer adoption of Jeuveau<sup>®</sup> and Evolysse<sup>™</sup>, the efficiency and operability of our digital platform, competition and market dynamics, our ability to successfully launch and commercialize our products in new markets, including the Evolysse<sup>™</sup> Hyaluronic Acid (HA) gels in the U.S. and Estyme <sup>®</sup> HA gels in Europe, our ability to maintain regulatory approvals of Jeuveau<sup>®</sup> and Evolysse<sup>™</sup> or obtain regulatory approvals for new product candidates or indications, our reliance on Symatese to achieve and/or maintain regulatory approval for the Evolysse<sup>™</sup> HA gel products in the U.S., and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled "Risk Factors" in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 expected to be filed with the Securities and Exchange Commission on or about August 5, 2025. These filings can be accessed online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If we do update or revise one or more of these statements, investors and others should not conclude that we will make additional updates or corrections.

Jeuveau<sup>®</sup> and Nuceiva<sup>®</sup>, are registered trademarks and Evolysse<sup>™</sup> is a trademark of Evolus, Inc.

Estyme<sup>®</sup> is a trademark of Symatese Aesthetics S.A.S.

------

###

**Evolus Contacts:**

<u>Investors:</u>

Nareg Sagherian

Vice President, Head of Global Investor Relations and Corporate Communications

Tel: 248-202-9267

Email: ir@evolus.com

<u>Media:</u>

Email: media@evolus.com

------

**Evolus, Inc.**

**Consolidated Statements of Operations and Comprehensive Loss**

**(in thousands, except loss per share data)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Revenue: |  |  |  |  |
| &nbsp;&nbsp;Product revenue, net | $68699 | $66222 | $136773 | $125186 |
| &nbsp;&nbsp;Service revenue | 688 | 687 | 1136 | 1056 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total net revenues | 69387 | 66909 | 137909 | 126242 |
| &nbsp;&nbsp;Cost of goods sold | 24067 | 19841 | 45934 | 38671 |
| Gross profit | 45320 | 47068 | 91975 | 87571 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;Selling, general and administrative | 56675 | 50152 | 113315 | 95275 |
| &nbsp;&nbsp;Research and development | 1837 | 2350 | 4049 | 4428 |
| &nbsp;&nbsp;Revaluation of contingent royalty obligation payable to Evolus Founders | (3914) | 1605 | (1763) | 3183 |
| &nbsp;&nbsp;Depreciation and amortization | 932 | 663 | 1756 | 1309 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 55530 | 54770 | 117357 | 104195 |
| Loss from operations | (10210) | (7702) | (25382) | (16624) |
| Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;Interest income | 479 | 1029 | 1189 | 1546 |
| &nbsp;&nbsp;Interest expense | (7207) | (4696) | (11622) | (9398) |
| &nbsp;&nbsp;Other income (expense), net | (151) | 62 | (94) | 107 |
| Loss before income taxes | (17089) | (11307) | (35909) | (24369) |
| &nbsp;&nbsp;Income tax expense | (53) | (43) | (125) | (90) |
| Net loss | $(17142) | $(11350) | $(36034) | $(24459) |
| Other comprehensive income (loss), net of tax: |  |  |  |  |
| &nbsp;&nbsp;Currency translation adjustment | 240 | (44) | 306 | (174) |
| Comprehensive loss | $(16902) | $(11394) | $(35728) | $(24633) |
| Net loss per share, basic and diluted | $(0.27) | $(0.18) | $(0.56) | $(0.40) |
| Weighted-average shares outstanding used to compute basic and diluted net loss per share | 64539 | 62725 | 64120 | 60761 |

---

------

**Evolus, Inc.**

**Summary of Consolidated Balance Sheet Data**

**(Unaudited, in thousands)**

---

| | | |
|:---|:---|:---|
| | **June 30, 2025** | **December 31, 2024** |
| &nbsp;&nbsp;Cash and cash equivalents | $61738 | $86952 |
| &nbsp;&nbsp;Accounts receivable, net | 47709 | 47682 |
| &nbsp;&nbsp;Inventories | 26457 | 12158 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 9066 | 4550 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current assets** | 144970 | 151342 |
| &nbsp;&nbsp;Noncurrent assets | 83833 | 81227 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $228803 | $232569 |
| &nbsp;&nbsp;Accounts payable and accrued expenses | $51261 | $50027 |
| &nbsp;&nbsp;Other current liabilities | 12489 | 12933 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total current liabilities** | 63750 | 62960 |
| &nbsp;&nbsp;Long-term portion of term loan, net of discount and issuance costs | 145475 | 121506 |
| &nbsp;&nbsp;Other noncurrent liabilities | 38230 | 42581 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities** | $247455 | $227047 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total stockholders' equity (deficit)** | $(18652) | $5522 |

---

**Evolus, Inc.**

**Summary of Consolidated Cash Flows**

**(Unaudited, in thousands)**

---

| | | | |
|:---|:---|:---|:---|
| | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** |
| &nbsp;&nbsp;Net cash (used in) provided by: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating activities | $(40423) | $(17085) | $(24791) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing activities | (4128) | (2051) | (2267) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financing activities | 19032 | 50143 | 20663 |
| Effect of exchange rates on cash and cash equivalents | 305 | (174) | 239 |
| Change in cash and cash equivalents | (25214) | 30833 | (6156) |
| Cash and cash equivalents, beginning of period | 86952 | 62838 | 67894 |
| Cash and cash equivalents, end of period | $61738 | $93671 | $61738 |

---

------

**Evolus, Inc.**

**Reconciliation of Gross Profit Margin to Adjusted Gross Profit Margin**

**(Unaudited, in thousands)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| Total net revenues | $69387 | $66909 | $137909 | $126242 |
| Cost of goods sold | 24067 | 19841 | 45934 | 38671 |
| Gross profit | 45320 | 47068 | 91975 | 87571 |
| *Gross profit margin* | *65.3%* | *70.3 %* | *66.7 %* | *69.4 %* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Add: Amortization of distribution right intangible asset | 806 | 764 | 1545 | 1527 |
| Adjusted gross profit | $46126 | $47832 | $93520 | $89098 |
| *Adjusted gross profit margin* | *66.5%* | *71.5 %* | *67.8 %* | *70.6 %* |

---

**Evolus, Inc.**

**Reconciliation of GAAP Operating Expenses to** 

**Non-GAAP Operating Expenses**

**(Unaudited, in thousands)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Three Months Ended March 31,** |
| | **2025** | **2024** | **2025** | **2024** | **2025** |
| **GAAP operating expense** | $55530 | $54770 | $117357 | $104195 | $61827 |
| Adjustments: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Revaluation of contingent royalty obligation | (3914) | 1605 | (1763) | 3183 | 2151 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation: |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Included in selling, general and administrative | 4346 | 5552 | 10095 | 10415 | 5749 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Included in research and development | 142 | 232 | 321 | 448 | 179 |
| &nbsp;&nbsp;Depreciation and amortization | 932 | 663 | 1756 | 1309 | 824 |
| **Non-GAAP operating expense** | $54024 | $46718 | $106948 | $88840 | $52924 |

---

------

**Evolus, Inc.**

**Reconciliation of GAAP (Loss) from Operations to** 

**Non-GAAP Income (Loss) from Operations**

**(Unaudited, in thousands)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** | **Six Months Ended<br>June 30,** |
| | **2025** | **2024** | **2025** | **2024** |
| **GAAP (loss) from operations** | $(10210) | $(7702) | $(25382) | $(16624) |
| Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Revaluation of contingent royalty obligation | (3914) | 1605 | (1763) | 3183 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Included in selling, general and administrative | 4346 | 5552 | 10095 | 10415 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Included in research and development | 142 | 232 | 321 | 448 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 932 | 663 | 1756 | 1309 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of distribution right intangible assets | 806 | 764 | 1545 | 1527 |
| **Non-GAAP income (loss) from operations** | $(7898) | $1114 | $(13428) | $258 |

---